Mackenzie Financial’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,001
| Closed | -$513K | – | 1715 |
|
|
2025
Q2 | $513K | Sell |
4,001
-12,195
| -75% | -$1.27M | ﹤0.01% | 1225 |
|
|
2025
Q1 | $1.43M | Buy |
16,196
+2,019
| +14% | +$197K | ﹤0.01% | 875 |
|
|
2024
Q4 | $1.24M | Buy |
14,177
+7,076
| +100% | +$648K | ﹤0.01% | 892 |
|
|
2024
Q3 | $657K | Buy |
7,101
+2,216
| +45% | +$220K | ﹤0.01% | 958 |
|
|
2024
Q2 | $527K | Buy |
4,885
+243
| +5% | +$24.3K | ﹤0.01% | 1002 |
|
|
2024
Q1 | $440K | Buy |
4,642
+170
| +4% | +$14.6K | ﹤0.01% | 1050 |
|
|
2023
Q4 | $412K | Hold |
4,472
| – | – | ﹤0.01% | 1051 |
|
|
2023
Q3 | $217K | Hold |
4,472
| – | – | ﹤0.01% | 1251 |
|
|
2023
Q2 | $281K | Hold |
4,472
| – | – | ﹤0.01% | 1191 |
|
|
2023
Q1 | $201K | Buy |
+4,472
| New | +$201K | ﹤0.01% | 1342 |
|
|
2022
Q4 | – | Sell |
-5,796
| Closed | -$382K | – | 1453 |
|
|
2022
Q3 | $382K | Buy |
5,796
+1,561
| +37% | +$100K | ﹤0.01% | 1012 |
|
|
2022
Q2 | $214K | Buy |
4,235
+886
| +26% | +$51.9K | ﹤0.01% | 1252 |
|
|
2022
Q1 | $214K | Buy |
3,349
+169
| +5% | +$12.1K | ﹤0.01% | 1262 |
|
|
2021
Q4 | $341K | Sell |
3,180
-5,019
| -61% | -$525K | ﹤0.01% | 1101 |
|
|
2021
Q3 | $843K | Buy |
8,199
+1,573
| +24% | +$146K | ﹤0.01% | 933 |
|
|
2021
Q2 | $583K | Buy |
+6,626
| New | +$607K | ﹤0.01% | 959 |
|
|
2016
Q3 | – | Sell |
-23,800
| Closed | -$482K | – | 678 |
|
|
2016
Q2 | $482K | Buy |
23,800
+1,700
| +8% | +$30.9K | ﹤0.01% | 763 |
|
|
2016
Q1 | $399K | Buy |
22,100
+7,600
| +52% | +$132K | ﹤0.01% | 692 |
|
|
2015
Q4 | $382K | Buy |
+14,500
| New | +$326K | ﹤0.01% | 711 |
|
Other funds holding BPMC
IA
HNB
Mackenzie Financial's BPMC Position: Q3 2025 in Review
Mackenzie Financial sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,001 shares — an estimated $513K sold.
Mackenzie Financial first reported a position in BPMC in Q4 2015 and held it in 19 quarters. The position peaked at $1.43M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Mackenzie Financial reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Mackenzie Financial sold 4,001 Blueprint Medicines shares in Q3 2025, an estimated $513K.
- Mackenzie Financial first reported a position in Blueprint Medicines in Q4 2015 and held it in 19 quarters.
- Mackenzie Financial's Blueprint Medicines position peaked at $1.43M in Q1 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Mackenzie Financial's 13F filing for Q3 2025, filed 13 Nov 2025.